TransDigm Group grants director David Barr 589 stock options
The options become exercisable gradually from September 30, 2027, subject to annual operating performance targets in each year.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TransDigm Group director David Barr received a grant of 589 stock options on November 3, 2026, covering 589 shares of common stock. His reported direct position after the award was 589 options. They have an exercise price of $1,208.04 per share and expire November 3, 2036. The options are exercisable at 20% per year over five years beginning September 30, 2027, subject to achievement of annual operating performance targets in each year.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1 | 589 | $0.00 | $0.00 |
Footnotes (1)
- F1. These options are exercisable at 20% per year over five years beginning September 30, 2027, subject to the achievement of annual operating performance targets in each year.
Key Figures
Key Terms
Stock Option financial
exercise price financial
annual operating performance targets technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many stock options did TransDigm Group director David Barr receive?
What is the exercise price of David Barr's TransDigm Group options?
When do David Barr's TransDigm Group options become exercisable?
AI-generated analysis. How Rhea-AI works. Not financial advice.